NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix Reports Full Year 2020 Financial Results And Highlights Operational Progress
    Preclinical data presented at AACR virtual special conference showed NBTXR3 combo over­comes anti-PD-1 resistance, pro­motes strong abscopal effect and long-term anti-cancer memory
    Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer



    June 4, 2021

    ASCO 2021

    More info
    May 4, 2021

    32nd Annual Cancer Progress Conference

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation